1-4 of 4
David Miller
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A75: The IMPaCT trial: Individualised Molecular Pancreatic Cancer Therapy. A pilot, randomized, open label Phase II trial assessing first line treatment with gemcitabine or personalized treatment based on tumour molecular signature in patients with metastatic pancreatic cancer.

Free
Lorraine Chantrill, Amber Johns, Adnan Nagrial, Venessa Chin, Angela Chou, Mark Pinese, Scott Mead, Val Gebski, Katrin Sjoquist, Chee Lee, Sonia Yip, Danielle Miller, Lucille Sebastian, Ray Asghari, Sandra Harvey, Nick Pavlakis, Sanjay Mukhedkar, Peter Grimison, David Miller, John Pearson, Nicola Waddell, Sean Grimmond, John Simes, Andrew Biankin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A75.
https://doi.org/10.1158/1535-7163.TARG-13-A75
Published: 01 November 2013
View articletitled, Abstract A75: The IMPaCT trial: Individualised Molecular Pancreatic Cancer Therapy. A pilot, randomized, open label Phase II trial assessing first line treatment with gemcitabine or personalized treatment based on tumour molecular signature in patients with metastatic pancreatic cancer.
Journal Articles

Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models

Free
Rachel M. Squillace, David Miller, Michelle Cookson, Scott D. Wardwell, Lauren Moran, David Clapham, Frank Wang, Tim Clackson, Victor M. Rivera
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (10): 1959–1968.
https://doi.org/10.1158/1535-7163.MCT-11-0273
Published: 09 October 2011
View articletitled, Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models
Open the PDF for Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models in another window
Includes: Supplementary data
Journal Articles

Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

Free
Victor M. Rivera, Rachel M. Squillace, David Miller, Lori Berk, Scott D. Wardwell, Yaoyu Ning, Roy Pollock, Narayana I. Narasimhan, John D. Iuliucci, Frank Wang, Tim Clackson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (6): 1059–1071.
https://doi.org/10.1158/1535-7163.MCT-10-0792
Published: 08 June 2011
View articletitled, Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Open the PDF for Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens in another window
Includes: Supplementary data
Journal Articles

Abstract B259: Combined targeting of FGFR2 and mTOR by AP24534 and ridaforolimus results in synergistic antitumor activity in FGFR2‐driven endometrial cancer models

Free
Joseph M. Gozgit, Rachel M. Squillace, Matthew J. Wong, David Miller, Scott Wardwell, Lori Berk, Lauren Moran, Qurish Mohemmad, Narayana I. Narasimhan, William C. Shakespeare, Frank Wang, Tim Clackson, Victor M. Rivera
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B259.
https://doi.org/10.1158/1535-7163.TARG-09-B259
Published: 10 December 2009
View articletitled, Abstract B259: Combined targeting of FGFR2 and mTOR by AP24534 and ridaforolimus results in synergistic antitumor activity in FGFR2‐driven endometrial cancer models